Poster Session B
Monday, October 9, 2017
5:15 p.m.–7:45 p.m.
Salons 3, 4, 5, and 6 of the Ray Dolby Ballroom

B01 Immune cell infiltrates differ by obesity in tumor and adjacent normal breast tissue in African American women with triple negative breast cancer. Asra Shaik, Wayne State University School of Medicine, Detroit, MI, United States.

B02 Intratumoral bidirectional transitions between epithelial and mesenchymal cells in triple-negative breast cancer. Mizuki Yamamoto, University of tokyo, Tokyo, Japan.

B03 Minor clones can drive polyclonal metastasis by affecting immune microenvironment. Michalina Janiszewska, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

B04 Palbociclib based combinatorial drug screening in ER positive cell lines identifies efficacious single agents and novel combinations with synergistic interactions. James Korkola, Oregon Health & Science University, Portland, OR, United States.

B05 Pathological complete response is an independent prognostic factor for locoregional recurrence in locally advanced breast cancer patients after neoadjuvant chemotherapy. Hsu-Huan Chou, Chang Gung Memorial Hospital, Taoyuan City, Taiwan.


B07 The role of IRF5 in mammary gland development and tumorigenesis. Dan Li, Feinstein Institute, Manhasset, NY, United States.

B08 The tumor microbiome of ER+ versus triple negative breast cancer. Juliana Noguti, Los Angeles Biomedical Research Institute, Torrance, CA, United States.

B09 Tumorigenic process of triple negative breast cancer analyzed by influence of BRCA1 deficiency. Dirce Carraro, A. C. Camargo Cancer Center, São Paulo, São Paulo, Brazil.

B11 HDAC6 as a therapeutic target in human breast cancer. Charles Clevenger, Virginia Commonwealth University, Richmond, VA, United States.

B13 Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence. Jessalyn Ubellacker, Department of Medicine, Harvard Medical School, Boston, MA, United States.
B14 Sprouty4 regulates the transition to invasive breast ductal carcinoma through ERK/MAPK signaling. Ethan Brock, Wayne State University School of Medicine, Detroit, MI, United States.

B15 Targeting androgen receptor N-terminal domain with ralaniten in breast cancer. Amy Tien, Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.


B17 Activating AMPK signaling by SCT-1015 to suppress tumor growth on triple negative breast cancer cells. Chung-Wai Shiau, National Yang-Ming University, Taipei, Taiwan.

B18 ADSL controls pyrimidine metabolism and triple negative breast tumorigenesis. Qing Zhang, UNC-Chapel Hill, Chapel Hill, NC, United States.


B20 Glutamine metabolic vulnerabilities define triple-negative from Luminal A breast cancer subsets. Jeff Holst, Centenary Institute, Camperdown, Nsw, Australia.

B21 Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer. Syn Yeo, University of Cincinnati, Cincinnati, OH, United States.

B22 Inducing cell state transitions in triple negative breast cancer (TNBC). Ser Yue Loo, Genome Institute of Singapore, Singapore, Singapore.

B23 Intravital optical imaging of tumor vascular oxygenation and metabolism in murine breast cancer xenografts of varying metastatic potential. Narasimhan Rajaram, University of Arkansas, Fayetteville, AR, United States.

B24 Met and VDAC1 as target for breast cancer therapy. Ilan Tsarfaty, Tel Aviv University, Tel Aviv, Israel.
Poster Session B
Monday, October 9, 2017
5:15 p.m.–7:45 p.m.
Salons 3, 4, 5, and 6 of the Ray Dolby Ballroom

B26 Thermally abused frying oil enhances metastatic progression in vivo and in vitro: a link to elevated fumarate levels. Jennifer Hughes, University of Illinois, Urbana, IL, United States.

B27 Transfection of mutant P53 promotes membrane translocation of GLUT1 and increases glucose uptake in MCF10A human breast epithelial cells. Sung Gwe Ahn, Gangnam Severance Hospital, Seoul, Korea, Korea, Republic Of.

B28 A cell non-autonomous aging mechanism in breast epithelia that increases susceptibility to cancer. Masaru Miyano, City of Hope, Duarte, CA, United States.

B29 An allelic series of rat mutations reveal a role of TOX3 in mammary gland development, obesity and breast cancer susceptibility. Bart Smits, Medical University of South Carolina, Charleston, SC, United States.

B31 Extracellular matrix, stiffness, miR-203, ZNF217 and mammographic density. Ivory Dean, University of California San Francisco, San Francisco, CA, United States.

B32 Stage of preneoplastic breast cancer progression impacts the efficacy of chemoprevention. Anjana Bhardwaj, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B33 Neoadjuvant chemotherapy promotes macrophage-induced Mena<sup>INV</sup>-dependent pro-metastatic changes in breast tumors. George Karagiannis, Albert Einstein College of Medicine, Bronx, NY, United States.

B34 Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer. Samantha Bevill, UNC Chapel Hill, Chapel Hill, NC, United States.

B35 Palbociclib treatment activates FAK and use of palbociclib in combination with the FAK inhibitor PF-562,271 enhances anti-tumor activity in ER positive breast cancer cells. Christina Addison, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

B36 Progesterone receptor signaling in estrogen receptor-positive breast cancer. Amy Young, Genentech, Inc., South San Francisco, CA, United States.

B37 The kinome of chemotherapy-resistant TNBC and identification of targetable kinases. Carolien Van Der Borden, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, United States.
B38 The role of BQ323636.1, a novel splice variant of NCOR2, in modulation of oxidative stress in breast cancer. Man Hong Leung, The University of Hong Kong, Hong Kong, Hong Kong.

B39 Therapeutic effect of anti-Progranulin (GP88) antibody AG01 in letrozole resistant and triple negative breast cancer cells. Rupa Guha, University of Maryland, Baltimore, Md - Maryland, United States.

B40 Translation initiation factor eIF2 serine 51 phosphorylation suppresses HER2-mediated tumorigenesis and increases sensitivity of HER2+ breast cancer to Trastuzumab therapy. Antonis Koromilas, Lady Davis Institute-McGill University, Montreal, QC, Canada.

B41 BP1 is an important biomarker in breast cancer. Patricia Berg, George Washington University, Washington, D.C., United States.

B42 Identification of CPT1A as a novel driver of proliferation in luminal breast cancer. Michael Gatza, Rutgers Cancer Institute, New Brunswick, NJ, United States.

B43 NF1 deficiency induces aggressive mammary carcinomas in a CRISPR rat model and correlates with poor outcome in sporadic human breast cancer. Carrie Graveel, Van Andel Research Institute, Grand Rapids, MI, United States.

B44 Role of EGFR/ERBB4 and MAPK signaling in modulating oncogenic potential of ER+ breast cancer cells overexpressing HER3 mutant. Rosalin Mishra, James L.Winkle college of pharmacy, Cincinnati, OH, United States.


B46 Targeting EZH2 reactivates a breast cancer subtype-specific antimetastatic transcriptional program. William Muller, McGill, Montreal, QC, Canada.

B47 Validation of novel breast cancer drivers using mammary stem cell based somatic mouse models. Wenjun Guo, Albert Einstein College of Medicine, New York City, NY, United States.
B48 Whole genome sequencing and transcriptomic analysis of MMTV-Neu and MMTV-PyMT mammary tumors. Eran Andrechek, Michigan State University, East Lansing, MI, United States.

B51 Genetic etiology of ER low/HER2- breast tumors. Rachel Ellsworth, Murtha Cancer Center, Bethesda, MD, United States.

B52 HIF-ZMYND8-BRD4 axis mediates breast cancer progression and metastasis. Yan Chen, UT Southwestern Medical Center, Dallas, TX, United States.

B53 Investigating genetic drivers of disease progression in invasive lobular carcinoma. Nilgun Tasdemir, University of Pittsburgh, Pittsburgh, PA, United States.

B54 Investigating Semaphorin 7a in hormone receptor positive breast cancer progression. Lyndsey Crump, University of Colorado- Denver, Aurora, CO, United States.

B55 Investigating the role of Semaphorin 7a in triple negative breast cancer cell invasion. Sarah Tarullo, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

B56 Isolation and characterization of Met-tyrosine kinase signaling modifier genes that dictate breast carcinoma development. Ilan Tsarfaty, Tel Aviv University, Tel Aviv, Israel.

B57 Micrtotubule dynamics regulates mammary gland morphogenesis and tumorigenesis via stathmin. Barbara Belletti, CRO-Aviano National Cancer Institute, Aviano, Italy.

B58 Modeling oncogenic events in breast cancer precursor cells to study cancer evolution and genomic instability. Justyna Kanska, Cedars Sinai Medical Center, Los Angeles, CA, United States.

B59 Multi-parametric imaging to evaluate human and mouse breast carcinoma in situ. Vidya Sinha, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B60 Omics profiling of CDK4/6 inhibitors reveals functionally important secondary targets of abemaciclib. Caitlin Mills, Harvard Medical School, Boston, MA, United States.

B62 Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in DCIS (ductal carcinoma in situ). Lina Ding, Dana-Farber Cancer Institute, Boston, MA, United States.
B63 Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: A systematic review. Ina Kjaer, Lillebaelt Hospital, Vejle, Denmark.

B64 Sox10 drives tumor progression in breast cancer by reprogramming mammary tumor cells into a state of plasticity resembling primitive neural crest cells. Christopher Dravis, Salk Institute for Biological Studies, La Jolla, CA, United States.

B66 The conditional requirement of HER3 in HER2-amplified breast cancers. Ana Ruiz-Saenz, University of California, San Francisco, San Francisco, CA, United States.

B67 The DLK1-DIO3 imprinted region regulates long-term proliferation in normal and malignant breast epithelium. Maider Zabala, Stanford University, Stanford, CA, United States.

B68 The effects of Ca^{2+} on HGF/SF induced breast tumor cells proliferation and motility in vitro and in vivo – Single cell and MRI analysis. Galia Tsarfaty, The Chaim Sheba Medical Center, Ramat Gan, Israel.

B69 The effects of patient-physician relationships on perceptions of breast cancer treatment in African American women. Alexandria Lauray, Clark Atlanta University, Atlanta, GA, United States.

B71 Transcriptomics reveal fibroblast-derived extracellular matrix molecules as strong contributors to ILC development and tumor microenvironment. Julia Houthuijzen, Netherlands Cancer Institute, Amsterdam, Netherlands.